Sigvotatug vedotin Phase 3 miss tests Pfizer’s case for integrin beta-6 targeted ADCs
Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.
Pharma & Biotech
Medical Devices & Diagnostics
Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?
Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.